Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Priority Review Vouchers Could Be Used Frequently Next Year

This article was originally published in The Pink Sheet Daily

Executive Summary

FDA requests enough pediatric rare disease priority review voucher user fees to fund three redemptions in fiscal year 2016.

You may also be interested in...



Orphan Designation Requests To Get Slower Reviews

FDA can't keep pace with requests, placing more pressure on sponsors to ensure submissions are complete.

Sanofi Diabetes Franchise Could Get Boost From Retrophin’s Voucher

Priority review ticket might be used on Type 2 diabetes combo LixiLan, expected to be filed later this year.

Pricing, Pediatrics, Pot: 21st Century Cures Amendments

Committee members didn’t even vote on any amendments besides the manager’s package, but proposals floated and withdrawn offer glimpse at potential fights to come.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS078220

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel